Ulixertinib (BVD-523) has shown early evidence of clinical activity in a phase I trial, that included both patients with NRAS-mutant melanoma and BRAF-mutant melanoma which progressed on or were refractory to BRAF and/or MEK inhibitors [76]. This evidence concerns the gene MAP2K7 and melanoma.